值得注意的是，和誉近日宣布，其研发的新型PRMT5*MTA抑制剂ABSK131，已在针对MTAP缺失的晚 期/转移性实体瘤患者的1期临床试验中完成首例患者给药。据悉，2024年12月，ABSK131获得美国食品 药品监督管理局的IND批准。2025年3月，ABSK131获中国国家药品监督管理局药品审评中心的IND批 准。 消息面上，和誉发布业绩，上半年收入6.12亿元人民币，同比增加23.1%；期内经调整利润3.36亿元， 同比增加56.03%；净利润3.28亿元，同比增加58.84%。公告称，收入主要为来自默克的授权收入。此 外，公司购回股份以提振市场信心及提升股东价值。截至2025年6月30日止6个月，公司共购回954.5万 股股份，累计金额7530万港元。于2024年，亦合计购回2259.4万股股份，累计金额6870万港元。 和誉-B(02256)绩后涨近7%，截至发稿，涨4.02%，报10.87港元，成交额1.46亿港元。 ...

Core Viewpoint - The company, He Yu-B (02256), experienced a nearly 7% increase in stock price following the release of its financial results, reflecting positive market sentiment driven by strong revenue and profit growth [1] Financial Performance - For the first half of the year, the company reported revenue of 612 million RMB, representing a year-on-year increase of 23.1% [1] - Adjusted profit for the period was 336 million RMB, up 56.03% year-on-year [1] - Net profit reached 328 million RMB, marking a 58.84% increase compared to the previous year [1] Share Buyback - The company has engaged in share buybacks to boost market confidence and enhance shareholder value, repurchasing a total of 9.545 million shares for 75.3 million HKD in the six months ending June 30, 2025 [1] - In 2024, the company repurchased an additional 22.594 million shares for a total of 68.7 million HKD [1] Research and Development - He Yu-B announced the completion of the first patient dosing in a Phase 1 clinical trial for its new PRMT5*MTA inhibitor, ABSK131, targeting late-stage/metastatic solid tumor patients with MTAP deletion [1] - The company received IND approval from the U.S. FDA for ABSK131 in December 2024 and from the China National Medical Products Administration in March 2025 [1]